Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue ; volume:14 ; number:3 ; day:22 ; month:5 ; year:2012 ; pages:1-9 ; date:6.2012
Arthritis Research & Therapy ; 14, Heft 3 (22.5.2012), 1-9, 6.2012
- Urheber
-
Gheorghe, Karina Roxana
- Beteiligte Personen und Organisationen
-
Sadique, Syed
Leclerc, Patrick
Idborg, Helena
Wobst, Ivonne
Catrina, Anca Irinel
Jakobsson, Per-Johan
Korotkova, Marina
SpringerLink (Online service)
- DOI
-
10.1186/ar3851
- URN
-
urn:nbn:de:1111-2016050322485
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gheorghe, Karina Roxana
- Sadique, Syed
- Leclerc, Patrick
- Idborg, Helena
- Wobst, Ivonne
- Catrina, Anca Irinel
- Jakobsson, Per-Johan
- Korotkova, Marina
- SpringerLink (Online service)
Ähnliche Objekte (12)
Variability in response to anti-rheumatic drugs
The Effect of Anti-rheumatic Drugs on the Skeleton
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serumy‐Glutamylcysteine Leve
Proteomic analysis of synovial fluid from rheumatic arthritis and spondyloarthritis patients
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serum γ ‐Glutamylcysteine Level
The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug
Variability in response to anti-rheumatic drugs
The Effect of Anti-rheumatic Drugs on the Skeleton
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serumy‐Glutamylcysteine Leve
Proteomic analysis of synovial fluid from rheumatic arthritis and spondyloarthritis patients
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serum γ ‐Glutamylcysteine Level
The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug
Variability in response to anti-rheumatic drugs
The Effect of Anti-rheumatic Drugs on the Skeleton
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serumy‐Glutamylcysteine Leve
Proteomic analysis of synovial fluid from rheumatic arthritis and spondyloarthritis patients
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serum γ ‐Glutamylcysteine Level
The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy